GlaxoSmithKline UK

Stockley Park West, Uxbridge, Middlesex, UB11 1BT
Telephone: +44 (0)800 221 441
Fax: +44 (0)208 990 4328
Medical Information e-mail: customercontactuk@gsk.com

Patient Information Leaflet last updated on the eMC: 16/07/2010
PIL Liskonum Tablets

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 16/07/2010 and displayed until Current
Reasons for adding or updating:
  • Change to date of revision
  • Change to manufacturer contact details
Updated on 23/04/2010 and displayed until 16/07/2010
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 25/01/2010 and displayed until 23/04/2010
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change of contra-indications
Updated on 04/08/2009 and displayed until 25/01/2010
Reasons for adding or updating:
  • Change to dosage and administration
  • Change to side-effects
  • Change to date of revision
Updated on 15/10/2008 and displayed until 04/08/2009
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change to dosage and administration
Updated on 14/11/2007 and displayed until 15/10/2008
Reasons for adding or updating:
  • Change to date of revision
  • Change due to user-testing of patient information
Updated on 27/10/2005 and displayed until 14/11/2007
Reasons for adding or updating:
  • Change to date of revision
  • Change to drug interactions
Updated on 29/03/2004 and displayed until 27/10/2005
Reasons for adding or updating:
  • Change to drug interactions
Updated on 02/05/2002 and displayed until 29/03/2004
Reasons for adding or updating:
  • Update to PIL
Updated on 10/08/2000 and displayed until 02/05/2002
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
   lithium carbonate